Anzeige
Mehr »
Donnerstag, 11.06.2026 - Börsentäglich über 12.000 News
Vier Bohrlöcher, vier Treffer - bestätigt sich hier ein neues Uran-System?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MiParabilis Medicines sets biotech record with $670m IPO
MiEli Lilly continues dealmaking roll with $1bn AlzeCure agreement
MiAditxt and Ignite announce merger plans with strategic partner
MiMHRA to roll out new AI sandbox for medicines development
DiWuXi AppTec hits back after being named in Pentagon's Chinese military list
DiGSK doubles down on oncology with $10.6bn Nuvalent takeover
DiJ&J to acquire Firefly Bio for $1bn to enhance oncology pipeline
DiPfizer's Hympavzi secures FDA expanded indications for haemophilia
DiJ&J secures extended NICE approval for Darzalex following earlier refusal
MoIncyte bolsters haematology portfolio in $2bn Vega buyout
MoRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics
MoADA26: key obesity readouts from the conference
MoSanofi and Owkin partner to develop next-generation biopharma AI agents
MoEC grants marketing authorisation for IntraBio's Aqneursa
FrParabilis eyes $475m IPO to push lead asset into Phase III
FrPfizer signs licence agreement with Chai for AI drug discovery
FrBiogen's salanersen gains FDA breakthrough therapy designation for SMA
04.06.Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership
04.06.Cellares and TScan to assess automated manufacturing of TSC-101 therapy
04.06.Regeneron and CytomX extend cancer therapy partnership to $4bn deal
03.06.US lawmakers reveal policy to curb collaboration with Chinese biotech
03.06.Contraline secures $92.5m to push male contraceptive into late-stage trials
03.06.AbbVie receives EC approval for Aquipta to treat migraine
03.06.Roche's giredestrant secures FDA priority review for breast cancer
02.06.ASCO26: In vivo oncology approaches continue to show promise